Frank S Czerwiec
Overview
Explore the profile of Frank S Czerwiec including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
45
Citations
2786
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Crawford M, McDonald B, Chen W, Chowdhry H, Contreras R, Reyes I, et al.
Biomedicines
. 2023 Dec;
11(12).
PMID: 38137386
Autonomous cortisol secretion (ACS) from an adrenal adenoma can increase the risk for comorbidities and mortality. The dexamethasone suppression test (DST) is the standard method to diagnose ACS. A multi-site,...
2.
Ostroff C, Perrone R, Czerwiec F
Clin J Am Soc Nephrol
. 2022 Aug;
17(10):1559-1562.
PMID: 35998976
No abstract available.
3.
Walsh L, Reilly J, Cornwall C, Gaich G, Gipson D, Heerspink H, et al.
Kidney Int Rep
. 2021 Oct;
6(10):2575-2584.
PMID: 34622097
Introduction: A critical unmet need exists for precision therapies for chronic kidney disease. GFB-887 is a podocyte-targeting, small molecule inhibitor of transient receptor potential canonical-5 (TRPC5) designed specifically to treat...
4.
Perrone R, Chapman A, Oberdhan D, Czerwiec F, Sergeyeva O, Ouyang J, et al.
Kidney Int Rep
. 2020 Jun;
5(6):801-812.
PMID: 32518862
Introduction: Tolvaptan, a treatment for autosomal dominant polycystic kidney disease (ADPKD), inhibits vasopressin V2 receptor signaling, which causes aquaretic adverse events (AAEs). The short-term efficacy and tolerability of a once-daily,...
5.
Perrone R, Chapman A, Oberdhan D, Czerwiec F, Sergeyeva O, Ouyang J, et al.
Kidney Int Rep
. 2020 Jun;
5(6):790-800.
PMID: 32518861
Introduction: Tolvaptan, for treatment of autosomal dominant polycystic kidney disease (ADPKD), is provided as immediate-release (IR) tablets administered twice daily in split-dose regimens to suppress urine osmolality to <300 mOsm/kg....
6.
Gansevoort R, van Gastel M, Chapman A, Blais J, Czerwiec F, Higashihara E, et al.
Kidney Int
. 2019 Mar;
96(1):159-169.
PMID: 30898339
In the TEMPO 3:4 Trial, treatment with tolvaptan, a vasopressin V2 receptor antagonist, slowed the increase in total kidney volume and decline in estimated glomerular filtration rate (eGFR) in autosomal...
7.
Edwards M, Blais J, Czerwiec F, Erickson B, Torres V, Kline T
Clin Kidney J
. 2019 Feb;
12(1):71-77.
PMID: 30746130
Background: The ability of unstandardized methods to track kidney growth in clinical trials for autosomal dominant polycystic kidney disease (ADPKD) has not been critically evaluated. Methods: The Tolvaptan Efficacy and...
8.
Edwards M, Chebib F, Irazabal M, Ofstie T, Bungum L, Metzger A, et al.
Clin J Am Soc Nephrol
. 2018 Jul;
13(8):1153-1161.
PMID: 30026287
Background And Objectives: In the 3-year Tolvaptan Efficacy and Safety in Management of ADPKD and Its Outcomes (TEMPO) 3:4 and 1-year Replicating Evidence of Preserved Renal Function: an Investigation of...
9.
Torres V, Gansevoort R, Czerwiec F
N Engl J Med
. 2018 Feb;
378(5):489-490.
PMID: 29385372
No abstract available.
10.
Devuyst O, Chapman A, Shoaf S, Czerwiec F, Blais J
Kidney Int Rep
. 2017 Dec;
2(6):1132-1140.
PMID: 29270521
Introduction: In the randomized placebo-controlled Tolvaptan Efficacy and Safety in Management of Autosomal Dominant Polycystic Kidney Disease and its Outcomes (TEMPO) 3:4 trial, tolvaptan slowed kidney growth and renal function...